Convergence Investment Partners LLC Has $2.45 Million Stake in Cencora, Inc. $COR

Convergence Investment Partners LLC lifted its stake in Cencora, Inc. (NYSE:COR) by 31.6% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,789 shares of the company’s stock after acquiring an additional 1,869 shares during the period. Convergence Investment Partners LLC’s holdings in Cencora were worth $2,447,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. raised its position in shares of Cencora by 160.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock valued at $2,262,956,000 after purchasing an additional 4,123,795 shares during the period. Norges Bank acquired a new stake in shares of Cencora in the fourth quarter worth $822,506,000. Marshall Wace LLP boosted its holdings in shares of Cencora by 518.9% during the 3rd quarter. Marshall Wace LLP now owns 1,995,118 shares of the company’s stock worth $623,534,000 after buying an additional 1,672,762 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Cencora by 528.9% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,475,859 shares of the company’s stock worth $461,250,000 after buying an additional 1,241,186 shares during the period. Finally, Viking Global Investors LP grew its stake in Cencora by 95.0% in the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after buying an additional 1,013,913 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Cencora news, Director Lauren M. Tyler acquired 550 shares of Cencora stock in a transaction dated Monday, June 22nd. The stock was bought at an average cost of $270.23 per share, with a total value of $148,626.50. Following the acquisition, the director owned 4,359 shares of the company’s stock, valued at approximately $1,177,932.57. The trade was a 14.44% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.38% of the company’s stock.

Cencora Price Performance

Shares of NYSE:COR opened at $303.65 on Tuesday. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54. The firm has a market capitalization of $59.08 billion, a PE ratio of 23.29, a PEG ratio of 1.71 and a beta of 0.58. The business’s 50 day moving average is $280.85 and its 200-day moving average is $317.26. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts predict that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora declared that its board has initiated a stock buyback program on Thursday, May 21st that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to buy up to 3.9% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s leadership believes its stock is undervalued.

Cencora Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were paid a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.8%. Cencora’s dividend payout ratio is currently 18.40%.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Citigroup dropped their target price on shares of Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Weiss Ratings cut shares of Cencora from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, June 30th. UBS Group raised their price target on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Barclays dropped their price objective on Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 10th. Finally, Wells Fargo & Company cut their price objective on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. Eleven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and an average target price of $367.75.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.